16.42 USD
↘ 0.04 (0.24%)AT CLOSE (11:59 AM EDT)
Immunic, Inc. Common Stock
IMUXNASDAQ • USD
16.32
↘ 0.10 (0.61%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
16.32
↘ 0.10 (0.61%)
Market: OPEN
IMUX is currently priced at $16.32. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation side, IMUX appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Aug 25, 2026.
Open?$16.50
High?$17.18
Low?$16.15
Prev. Close?$16.46
Volume?231.1K
Avg. Volume?163.7K
VWAP?$16.59
Rel. Volume?1.41x
Bid / Ask
Bid?$13.89 × 100
Ask?$18.94 × 100
Spread?$5.05
Midpoint?$16.42
Valuation & Ratios
Market Cap?224.6M
Shares Out?13.6M
Float?120.7M
Float %?88.6%
P/E Ratio?N/A
P/B Ratio?1.76
EPS?-$8.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Address
1200 AVENUE OF THE AMERICAS
NEW YORK, X1 10036
Phone: (332) 255-9818
NEW YORK, X1 10036
Phone: (332) 255-9818
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?56
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.16Distress
Confidence?49%Low
Short InterestHigh
Short % of Float?1.06%Low
Short Interest?1.3M
Days to Cover?7.0
Free Float120.7M
Avg Daily Volume182.2K
Settlement Date2026-08-14
Financial Health
Current Ratio?5.05Strong
Quick Ratio?5.05Strong
Cash Ratio?4.96Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.76CHEAP▾
Peers100
S&P81
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-87.5%WEAK▾
S&P3
ROA?-70.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-88049000
Enterprise Value?$69.5M
Fundamentals ratios updated end of day